<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1408">
  <stage>Registered</stage>
  <submitdate>14/12/2006</submitdate>
  <approvaldate>14/12/2006</approvaldate>
  <nctid>NCT00412360</nctid>
  <trial_identification>
    <studytitle>Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)</studytitle>
    <scientifictitle>Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2U01HL069294</secondaryid>
    <secondaryid>BMTCTN0501</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myelogenous Leukemia</healthcondition>
    <healthcondition>Acute Lymphocytic Leukemia</healthcondition>
    <healthcondition>Chronic Myelogenous Leukemia</healthcondition>
    <healthcondition>Myelodysplastic Syndrome</healthcondition>
    <healthcondition>Natural Killer Cell Lymphoblastic Leukemia/Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Single Umbilical Cord Blood Unit Transplant
Other interventions - Double Umbilical Cord Blood Unit Transplant
Treatment: other - Total Body Irradiation
Treatment: drugs - Cyclophosphamide
Treatment: drugs - Fludarabine
Treatment: drugs - Cyclosporine A
Treatment: drugs - Mycophenolate Mofetil

Experimental: Single Cord Blood Transplant - Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil

Experimental: Double Cord Blood Transplant - Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil


Other interventions: Single Umbilical Cord Blood Unit Transplant
Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF

Other interventions: Double Umbilical Cord Blood Unit Transplant
Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF

Treatment: other: Total Body Irradiation
The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.

Treatment: drugs: Cyclophosphamide
Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.

Treatment: drugs: Fludarabine
Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.

Treatment: drugs: Cyclosporine A
CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.

Treatment: drugs: Mycophenolate Mofetil
MMF will be given at a dose of 1 gram IV q 8 hours if &gt; 50 kg or 15 mg/kg IV q 8 hours if &lt; 50 kg beginning the morning of Day -3.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Year 1</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-free Survival - Disease-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neutrophil Engraftment - Neutrophil engraftment is defined as achieving an ANC = 500/mm3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment.</outcome>
      <timepoint>Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Graft-versus-host Disease (GVHD) - Incidences of grade II - IV and III - IV acute GVHD at Day 100 will be graded according to the BMT CTN Manual of Procedures (MOP).</outcome>
      <timepoint>Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic GVHD - Incidences of chronic GVHD will be scored according to the BMT CTN MOP.</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related Mortality</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Infections</outcome>
      <timepoint>Year 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse - Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features.</outcome>
      <timepoint>Year 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Platelet Engraftment - Platelet engraftment to 50,000/mL</outcome>
      <timepoint>Day 180</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Engraftment Syndrome</outcome>
      <timepoint>Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chimerism</outcome>
      <timepoint>28, 42, 60, 180, 365 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immune Reconstitution</outcome>
      <timepoint>100 days, 6 months, 1 and 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Two partially HLA-matched UCB units. Units must be HLA-matched minimally at 4 of 6
             HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high
             resolution by molecular typing) loci with the patient, and the units must be
             HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with each other (using same resolution of
             molecular typing as indicated above). Two appropriately HLA-matched units must be
             available such that one unit delivers a pre-cryopreserved nucleated cell dose of at
             least 2.5 x 10^7 per kilogram and the second unit at least 1.5 x 10^7 per kilogram.

          -  Acute myelogenous leukemia (AML) at the following stages:

               1. High risk first complete remission (CR1), defined as the following:

                    -  Having preceding myelodysplasia (MDS)

                    -  High risk cytogenetics (high risk cytogenetics: del (5q) -5, -7, abn (3q), t
                       (6;9) complex karyotype [at least 5 abnormalities],)the presence of a high
                       FLT3 ITD-AR (&gt; 0.4)

                    -  Requiring more than 1 cycle of chemotherapy to obtain complete remission
                       (CR);

                    -  FAB M6

               2. Second or greater CR

               3. First relapse with less than 25% blasts in bone marrow

               4. Morphologic complete remission with incomplete blood count recovery

          -  Therapy-related AML for which prior malignancy has been in remission for at least 12
             months

          -  Acute lymphocytic leukemia (ALL) at the following stages:

               1. High risk first remission, defined as one of the following conditions:

                    -  Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)

                    -  Mixed lineage leukemia (MLL) rearrangement with slow early response (defined
                       as having M2 [5-25% blasts] or M3 [more than 25% blasts on bone marrow
                       examination on Day 14 of induction therapy])

                    -  Hypodiploidy (less than 44 chromosomes or DNA index less than 0.81)

                    -  End of induction M3 bone marrow

                    -  End of induction M2 with M2-3 at Day 42

                    -  Evidence of minimal residual disease (MRD). If a patient's only high risk
                       criterion is MRD, approval by a protocol chair or protocol officer is
                       required for enrollment. For COG centers, this will only be for MRD greater
                       than 1 percent by flow MRD at the end of extended induction.

               2. High risk second remission, defined as one of the following conditions:

                    -  Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)

                    -  Bone marrow relapse less than 36 months from induction

                    -  T-lineage relapse at any time

                    -  Very early isolated central nervous system (CNS) relapse (6 months from
                       diagnosis)

                    -  Slow reinduction (M2-3 at Day 28) after relapse at any time

                    -  Evidence of minimal residual disease (MRD). If a patient's only high risk
                       criterion is MRD, approval by a protocol chair or protocol officer is
                       required for enrollment. For COG centers, this will only be for MRD greater
                       than 1 percent by flow MRD at the end of extended induction.

               3. Any third or subsequent CR

          -  NK cell lymphoblastic leukemia in any CR

          -  Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have
             less than 25% blasts in bone marrow (BM)

          -  Myelodysplastic syndrome (MDS) at any stage

          -  Chronic myelogenous leukemia (CML) in chronic or accelerated phase

          -  All patients with evidence of CNS leukemia must be treated and be in CNS CR to be
             eligible for study.

          -  Patients 16 years old or older must have a Karnofsky score of at least 70% and
             patients younger than 16 years old must have a Lansky score of at least 70%.

          -  Patients with adequate physical function as measured by:

               1. Cardiac: Left ventricular ejection fraction greater than 40% or shortening
                  fraction greater than 26%

               2. Hepatic: Bilirubin no more than 2.5 mg/dL; alanine aminotransferase (ALT),
                  aspartate aminotransferase (AST), and alkaline phosphatase (ALP) no more than 5
                  times the upper limit of normal (ULN)

               3. Renal: Serum creatinine within normal range for age, or if serum creatinine is
                  outside normal range for age, then renal function (creatinine clearance or GFR)
                  greater than 70 mL/min/1.73 m^2

               4. Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced
                  expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater
                  than 50% of predicted value (corrected for hemoglobin); if unable to perform
                  pulmonary function tests, then O2 saturation greater than 92% of room air</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant (ß-positive human chorionic gonadotropin [HCG]) or breastfeeding

          -  Evidence of HIV infection or HIV positive serology

          -  Current uncontrolled bacterial, viral, or fungal infection (currently taking
             medication and progression of clinical symptoms)

          -  Autologous transplant less than 12 months prior to enrollment

          -  Prior autologous transplant for the disease for which the UCB transplant will be
             performed

          -  Prior allogeneic hematopoietic stem cell transplant

          -  Active malignancy other than the one for which the UCB transplant is being performed
             within 12 months of enrollment

          -  Inability to receive TBI

          -  Requirement of supplemental oxygen

          -  HLA-matched related donor able to donate</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>224</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Children's Hospital at Westmead - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Medical College of Wisconsin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Heart, Lung, and Blood Institute (NHLBI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Blood and Marrow Transplant Clinical Trials Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Marrow Donor Program</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a Phase III, randomized, open-label, multi-center, prospective study of single
      umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric
      patients with hematologic malignancies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00412360</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mary Horowitz, MD, MS</name>
      <address>Center for International Blood and Marrow Transplant Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>